Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ren Zhang has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of Kukoamine B from Lycii Radicis Cortex as a PD-L1 inhibitor against lung cancer

    by Meng Liu, Wanwan He, Lisheng Zhang, Meiling Chen, Yu Wei, Na Huang, Danna Zheng, Shuxian Wang, Wen Zhang, Na Liu, et al.

  • Open Access

    Kukoamine B Inhibits EMT in Lung Adenocarcinoma Cells by Regulating Intracellular PD-L1-Mediated p65 Nuclear Translocation

    by Congyan Hou, Jingqin Chen, Lisheng Zhang, Qiuyin Huang, Junnuo Xu, Ren Zhang, Yanli He

    Cortex Lycii Radicis, a medicinal plant, has been reported to inhibit epithelial–mesenchymal transition (EMT) and exhibit anti-lung cancer properties. Our previous study identified its major compound, Kukoamine B (KuB), as an inhibitor of membrane PD-1/PD-L1 interaction, thereby restoring T-cell function. However, the effect of KuB on EMT and the underlying mechanism thereof remain unknown. Herein, we show that PD-L1 overexpression enhances the proliferation, migration, and EMT of LUAD cells, upregulating N-cadherin and Vimentin, while downregulating E-cadherin. Mechanistically, PD-L1 directly binds phosphorylated p65 (p-p65) and facilitates p65 nuclear translocation, an interaction confirmed by molecular simulations. We found that KuB disrupts the PD-L1/p65 complex, impedes p65 nuclear translocation, and suppresses EMT, proliferation, and migration in LUAD cells. These inhibitory effects were reversed by PD-L1 overexpression. We therefore conclude that KuB suppresses EMT in LUAD by targeting intracellular PD-L1, blocking PD-L1–p65 interaction and nuclear translocation of p65.

  • Open Access

    Integrated Bioinformatics Analysis and Cellular Experimental Validation Identify Lipoprotein Lipase Gene as a Novel Biomarker for Tumorigenesis and Prognosis in Lung Adenocarcinoma

    by Wanwan He, Meilian Wei, Yan Huang, Junsen Qin, Meng Liu, Na Liu, Yanli He, Chuanbing Chen, Yali Huang, Heng Yin, et al.

    Lung adenocarcinoma (LUAD) is one of the leading causes of death worldwide, and thus, more biomarker and therapeutic targets need to be explored. Herein, we aimed to explore new biomarkers of LUAD by integrating bioinformatics analysis with cell experiments. We firstly identified 266 druggable genes that were significantly differentially expressed between LUAD tissues and adjacent normal lung tissues. Among these genes, SMR analysis with p-value correction suggested that declining lipoprotein lipase (LPL) levels may be causally associated with an elevated risk of LUAD, which was corroborated by co-localization analysis. Analyses of clinical data showed that LPL in lung cancer tissues has considerable diagnostic value for LUAD, and elevated LPL levels were positively associated with improved patient survival outcomes. Cell experiments with an LPL activator proved these findings; the activator inhibited the proliferation and migration of lung cancer cells. Next, we found that LPL promoted the infiltration of immune cells such as DCs, IDCs, and macrophages in LUAD by mononuclear sequencing analysis and TIMER2.0. Meanwhile, patients with low levels of LPL expression demonstrated superior immunotherapeutic responses to anti-PD-1 therapy. We conclude that LPL acts as a diagnostic and prognostic marker for LUAD.


  • Lycii Radicis Cortex suppresses the growth of non-small cell lung cancer via enhancing the anti-tumor immunity

    by Heng Yin, Meng Liu, Yaling Zhao, Haitao Wu, Danna Zheng, Zhenhui Guo, Ying Zhou, Shaofeng Wu, Chuanbing Chen, Lei Zhang, et al.

    Lycii Radicis Cortex (LRC) is a medicinal and food homologous plant with various pharmacological activities, including anti-tumor effects. This study explores the anti-tumor effect of LRC on non-small cell lung cancer (NSCLC) and its molecular mechanism using mice bearing Lewis lung carcinoma cells. LRC significantly suppressed the growth of NSCLC. Besides, RNA sequencing of mice tumors and hematoxylin & eosin and immunofluorescence staining revealed that LRC promoted the infiltration of T lymphocytes, specifically GZMB+CD8+T lymphocytes, in tumor tissues. The Gene Set Enrichment Analysis of spleen RNA indicated that LRC up-regulated PD-1-downstream pathways, suggesting that LRC exerted its effects through the PD-L1/PD-1 pathway. Further experiments revealed that LRC interacted with PD-L1, blocking PD-L1/PD-1 binding and thus restoring the T cell killing activity on tumor cells. Together, these results support using LRC as healthy food to improve anti-tumor immunity in patients with NSCLC.


  • Open Access

    TIMM9 as a prognostic biomarker in multiple cancers and its associated biological processes

    by Lisheng Zhang, Yan Huang, Yanting Yang, Birong Liao, Congyan Hou, Yiqi Wang, Huaiyu Qin, Huixiang Zeng, Yanli He, Jiangyong Gu, et al.

    TIMM9 has been identified as a mediator of essential functions in mitochondria, but its association with pan-cancer is poorly understood. We herein employed bioinformatics, computational chemistry techniques and experiments to investigate the role of TIMM9 in pan-cancer. Our analysis revealed that overexpression of TIMM9 was significantly associated with tumorigenesis, pathological stage progression, and metastasis. Missense mutations (particularly the S49L variant), copy number variations (CNV) and methylation alterations in TIMM9 were found to be associated with poor cancer prognosis. Moreover, TIMM9 was positively related with cell cycle progression, mitochondrial and ribosomal function, oxidative phosphorylation, TCA cycle activity, innate and adaptive immunity. Additionally, we discovered that TIMM9 could be regulated by cancer-associated signaling pathways, such as the mTOR pathway. Using molecular simulations, we identified ITFG1 as the protein that has the strongest physical association with TIMM9, which show a promising structural complement.


  • miR-122-3p targets UBE2I to regulate the immunosuppression of liver cancer and the intervention of Liujunzi formula

    by Zhenhui Guo, Yiqi Wang, Wanting Qin, Yin Heng, Xi Chen, Na Liu, Jinzhe Li, Haitao Wu, Ying Zhou, Ren Zhang, et al.


  • Open Access

    Inhibitory Effects and Mechanism of the Natural Compound Diaporthein B Extracted from Marine-Derived Fungi on Colon Cancer Cells

    by Peihua Tang, Dandan Liu, Zheli Wu, Hui Cui, Ren Zhang, Zaoyuan Kuang

    This study aimed to investigate the inhibitory effects and mechanism of diaporthein B (DTB), a natural compound extracted from the fungus Penicillium sclerotiorum GZU-XW03-2, on human colon cancer cells. The inhibitory effect of DTB at different concentrations on the proliferation of colon cancer cells HCT116 and LOVO was detected at 24 and 48 h. The effect of cell migration and clone formation ability were detected by cell scratch and plate cloning experiments. Morphological changes were observed by Hoechst 33342 and Annexin-V/PI staining, and flow cytometry was used to detect the proportion of apoptotic cells. DTB significantly inhibited colon cancer cell proliferation, migration, and apoptosis in a dose-dependent manner without significant effects on normal colonic epithelial cells NCM460. The IC50 inhibition effect can be achieved after treatment with 3 μmol/L DTB for 24 h. Compared with the blank group, the migration and clonal-forming ability of colon cancer cells in the DTB group was significantly decreased (p < 0.01), while the apoptotic cells were significantly increased (p < 0.01) in a concentration-dependent manner. DTB can inhibit the proliferation and migration of human colon cancer cells HCT116 and LOVO and promote the apoptosis of human colon cancer cells.


  • Study on the mechanism of Cortex Lycii on lung cancer based on network pharmacology combined with experimental validation

    by Zhenhui Guo, Heng Yin, Tong Wu, Shaofeng Wu, Lingyun Liu, Lei Zhang, Yanli He, Ren Zhang, Na Liu


  • Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1α pathway

    by Jingfeng Liu, Xiaofei Huang, Dandan Liu, Kaiyuan Ji, Cheng Tao, Ren Zhang, Jian Chen


  • Open Access

    Network Pharmacology and Experimental Evidence Reveal Dioscin Suppresses Proliferation, Invasion, and EMT via AKT/GSK3b/mTOR Signaling in Lung Adenocarcinoma

    by Wenli Mao, Heng Yin, Wenya Chen, Tingxiu Zhao, Shaofeng Wu, He Jin, Biaoyan Du, Yuhui Tan, Ren Zhang, Yanli He

    Purpose: Dioscin, a natural glycoside derived from many plants, has been proved to exert anti-cancer activity. Several studies have found that it reverses TGF-β 1-induced epithelial–mesenchymal transition (EMT). Whether dioscin can reverse EMT by pathways other than TGF-β is still unknown. Methods: We used network-based pharmacological methods to systematically explore the potential mechanisms by which dioscin acts on lung cancer. Cell Counting Kit-8 assay, scratch healing, Transwell assay, Matrigel invasion assay, immunofluorescence assay, and Western blotting were employed to confirm the prediction of key targets and the effects of dioscin on EMT. Results: Here, using network-based pharmacological methods, we found 42 possible lung cancer-related targets of dioscin, which were assigned to 98 KEGG pathways. Among the 20 with the lowest p-values, the PI3K-AKT signaling pathway is involved and significantly related to EMT. AKT1 and mTOR, with high degrees (reflecting higher connectivity) in the compound-target analysis, participate in the PI3K-AKT signaling pathway. Molecular docking indicated the occurrence of dioscin-AKT1 and dioscin-mTOR binding. Functional experiments demonstrated that dioscin suppressed the proliferation, migration, invasion, and EMT of human lung adenocarcinoma cells in a dose-dependent manner, without TGF-β stimulation. Furthermore, we determined that dioscin downregulated p-AKT, p-mTOR and p-GSK3β in human lung adenocarcinoma cells without affecting their total protein levels. The PI3K inhibitor LY294002 augmented these changes. Conclusion: Dioscin suppressed proliferation, invasion and EMT of lung adenocarcinoma cells via the inactivation of AKT/mTOR/GSK3β signaling, probably by binding to AKT and mTOR, and inhibiting their phosphorylation.